Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley Fever in adults: an open-label, non-randomised, first-in-human phase 1 clinical trial

BACKGROUND: Rift Valley Fever (RVF) is a viral epidemic illness prevalent in Africa that can be fatal or result in debilitating sequelae in humans. No vaccines are available for human use. We evaluated the safety and immunogenicity of a non-replicating simian adenovirus (ChAdOx1)-vectored RVF vaccin...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Lancet Infect Dis
Auteurs principaux: Jenkin, Daniel, Wright, Daniel, Folegatti, Pedro M., Platt, Abigail, Poulton, Ian, Lawrie, Alison, Tran, Nguyen, Boyd, Amy, Turner, Cheryl, Gitonga, John N., Karanja, Henry K., Mugo, Daisy, Ewer, Katie J., Bowden, Thomas A., Gilbert, Sarah C., Charleston, Bryan, Kaleebu, Pontiano, Hill, Adrian V. S., Warimwe, George M.
Format: Artigo
Langue:Inglês
Publié: 2023
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7614834/
https://ncbi.nlm.nih.gov/pubmed/37060917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(23)00068-3
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires